Cargando…
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles, and patient characteristics (female gender, younger age, low alcohol consumption, history of motion sickn...
Autor principal: | Navari, Rudolph M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004672/ https://www.ncbi.nlm.nih.gov/pubmed/21188135 |
Ejemplares similares
-
Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
por: Navari, Rudolph M
Publicado: (2014) -
Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron
por: Bajetta, Emilio, et al.
Publicado: (2009) -
Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
por: Navari, Rudolph M.
Publicado: (2015) -
Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron
por: Zhou, Michelle, et al.
Publicado: (2015) -
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy
por: Celio, Luigi, et al.
Publicado: (2015)